Dalton Pharma Services and The Henry M. Jackson Foundation Announce a Services Agreement for the Advancement of Military Medicine
Dalton Pharma Services announced the company has entered into a Contract for Service with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to supply and provide sterile fill services for a cGMP grade capsule conjugate vaccine against Campylobacter jejuni developed by the Naval Medical Research Center (NMRC) and Prof. Mario Monteiro (University of Guelph).
Dalton will scale up the conjugation and purification process of a capsule-protein conjugate vaccine intended for use in Phase 1 human clinical trials conducted by NMRC.
“Our expertise and capabilities in conjugation chemistry, sterile API manufacturing and our strength in aseptic filling, solidified the manufacturing agreement," said Peter Pekos, President and CEO of Dalton. “Dalton is committed to supporting the efforts of the Navy and the University of Guelph for novel vaccine research and development.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.